Systemic bioavailability of fluticasone proprionate
- PMID: 11678793
- PMCID: PMC2014587
- DOI: 10.1046/j.0306-5251.2001.01456.x-i3
Systemic bioavailability of fluticasone proprionate
Comment on
-
Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations.Br J Clin Pharmacol. 2001 Jan;51(1):103-5. doi: 10.1046/j.1365-2125.2001.01325.x. Br J Clin Pharmacol. 2001. PMID: 11167672 Free PMC article. Clinical Trial.
References
-
- O'Brien JG, Dong BJ, Coleman RL, Gee L, Balano KB. A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus-infected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia. Clin Infect Dis. 1997;24:854–859. - PubMed
-
- Girardin E, Vial T, Pham E, Evreux JC. Hypoglycémies induites par les sulfamides hypoglycémiants. Recensement par les centres Régionaux de pharmacovigilance français de. 1985 à 1990. Ann Med Interne. 1992;143:11–17. - PubMed
-
- Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokin. 2000;38:111–180. - PubMed
-
- Rieutord A, Stuppans I, Shenfield GM, Gross AS. Glicazide hydroxylation by rat liver microsomes. Xenobiotica. 1995;25:1345–1354. - PubMed
-
- Komatsu K, Ito K, Nakajima Y, et al. Prediction of in vivo drug–drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab Dispos. 2000;28:475–484. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources